Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended
following percutaneous coronary intervention (PCI) to reduce the risk for major adverse …

P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) represents the standard of
care for the prevention of ischemic events in patients with coronary artery disease, in …

Current guidelines recommend dual antiplatelet therapy (DAPT) consisting of aspirin and a
P2Y12 inhibitors following percutaneous coronary intervention (PCI). CYP2C19 genotype …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel,
prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce …

Despite the development of newer and more potent antiplatelet medications, clopidogrel
remained the most prescribed P2Y12 inhibitor after percutaneous coronary intervention …

Dual antiplatelet therapy comprising aspirin and a P2Y12 receptor inhibitor is widely used
for patients who underwent percutaneous coronary intervention (PCI). 1 Although …

Oral P2Y12 inhibitors represent the cornerstone of treatment for patients undergoing
percutaneous coronary interventions (PCI)[1]. In patients undergoing PCI, oral P2Y12 …

Background Guidelines favour ticagrelor or prasugrel over clopidogrel in patients with
myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary …

The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently,
some patients are at increased risk of recurrent ischemic events during treatment. This …

Dual antiplatelet treatment (DAPT) with aspirin and a P2Y12 receptor inhibitor is the current
mainstay of treatment for patients undergoing percutaneous coronary intervention (PCI) …